The prevalence and severity of depression among people with autoimmune diseases like rheumatoid arthritis, psoriasis, Crohn’s disease, and systemic lupus erythematosus (SLE) appears to be high, according to data from recent studies.
“Researchers have theorized that the increased immune activation associated with depression is a plausible biological pathway that could trigger autoimmune diseases,” explains Andrea L. Roberts, PhD. “Despite this possible connection, few analyses have looked at temporal associations between depression and subsequent development of autoimmune disease.”
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.